Human papilloma virus vaccine dose and schedule
Reading File
Searching the Web
HPV vaccine dose schedule 2025 ACIP recommendations
Finding Sources
Searching PubMed
"HPV vaccine" AND "single dose" AND schedule
Reading File
I now have comprehensive information from both the medical library and the latest 2025-2026 updates. Here is the full answer:
HPV Vaccine - Dose and Schedule
Available Vaccines
Only one HPV vaccine is currently marketed in the United States:
- Gardasil 9 (9vHPV) - 9-valent, covers HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58
- Previously available: Gardasil (4vHPV) and Cervarix (2vHPV) - no longer marketed in the US
Current U.S. CDC Schedule (as of January 2026)
Important update: In January 2026, the CDC - following a directive from HHS - revised the childhood immunization schedule to recommend a single dose of HPV vaccine for all children at ages 11-12 years. This change was made outside the usual ACIP evidence-review process and was based on data from the ESCUDDO trial (NEJM, 2025), which demonstrated non-inferiority of one dose vs. two doses. Professional societies including ASCCP have noted this change while raising concerns about its process.
| Population | Doses | Timing |
|---|---|---|
| Routine (children, all) | 1 dose | At age 11-12 years |
| Can start as early as | 1 dose | Age 9 years |
Prior Schedule (Still Relevant for High-Risk Groups / Catch-Up / Adults)
The previous standard schedule (still used as a reference for immunocompromised patients, older adolescents, and adults) was:
2-Dose Schedule
- Who: Persons starting vaccination before age 15
- Timing: Dose 1, then Dose 2 at 6-12 months after Dose 1 (minimum interval: 5 months)
3-Dose Schedule
- Who: Persons starting vaccination at age 15 or older, or immunocompromised individuals (including HIV infection, regardless of CD4 count)
- Timing:
- Dose 1: Month 0
- Dose 2: 1-2 months after Dose 1
- Dose 3: 6 months after Dose 1
Age Recommendations
| Age Group | Recommendation |
|---|---|
| 9-12 years | Routine vaccination (all children) |
| 13-26 years | Catch-up vaccination if not previously vaccinated |
| 27-45 years | Shared clinical decision-making (benefits may be limited) |
| >45 years | Not recommended |
Key Points
- Dose: 0.5 mL intramuscular (IM), preferably in the deltoid muscle
- Vaccines are most effective before exposure to HPV - ideally before sexual debut
- HPV vaccines do not have therapeutic effect on existing HPV infection or disease
- Antibody titers are higher when given at ages 9-15 compared to 16-26 years
- Protection has been demonstrated for up to 8-10 years with no evidence of waning
WHO / International Schedule
The WHO (2022) recommends:
- 1 or 2 doses for ages 9-20 years
- 2 doses for ages 9+ with 6-month interval (standard)
- Single dose option for ages 9-20 (67 countries have now adopted single-dose schedules)
Recent Evidence Supporting Single-Dose
A 2024 meta-analysis (PMID 38180991) of 902,368 vaccinated women found that one-dose HPV vaccination had high clinical effectiveness. The key ESCUDDO RCT (Kreimer et al., NEJM 2025, PMID 41337735) demonstrated non-inferiority of one dose vs. two doses of HPV vaccine. A 2025 systematic review (PMID 40610947) further supported comparable effectiveness and immunogenicity of single-dose regimens.
Note: The January 2026 single-dose revision applies to the routine "all children" schedule. For adults 27-45, immunocompromised persons, and catch-up scenarios, providers should consult the latest guidelines as specific recommendations are still evolving.
- Red Book 2021, p. 717-718
This is a shared conversation. Sign in to Orris to start your own chat.